Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BEAM
stocks logo

BEAM

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
10.82M
-64.02%
-1.201
+10.17%
15.32M
+105.07%
-1.028
-17.08%
15.47M
+82.74%
-1.044
+4.42%
Estimates Revision
The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -15.4% over the past three months. During the same period, the stock price has changed by 38.46%.
Revenue Estimates for FY2025
Revise Downward
down Image
-15.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.96%
In Past 3 Month
Stock Price
Go Up
up Image
+38.46%
In Past 3 Month
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 41.90 USD with a low forecast of 21.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 41.90 USD with a low forecast of 21.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
2 Hold
0 Sell
Strong Buy
Current: 28.910
sliders
Low
21.00
Averages
41.90
High
80.00
Current: 28.910
sliders
Low
21.00
Averages
41.90
High
80.00
Evercore ISI
Outperform
initiated
$35
2025-11-24
Reason
Evercore ISI
Price Target
$35
2025-11-24
initiated
Outperform
Reason
Evercore ISI initiated coverage of Beam Therapeutics with an Outperform rating and $35 price target. BEAM-302 offers "a potentially game-changing approach for AATD," with early data showing impressive levels of corrected AAT production, says the analyst, who calls upcoming data due in Q1 of 2026 "crucial."
Clear Street
Buy
maintain
$34 -> $37
2025-11-04
Reason
Clear Street
Price Target
$34 -> $37
2025-11-04
maintain
Buy
Reason
Clear Street raised the firm's price target on Beam Therapeutics to $37 from $34 and keeps a Buy rating on the shares following the Q3 report. BEAM-103 has dosed the first patient in a healthy volunteer study while the next major catalyst for the shares being the interim update from BEAM-302 in early 2026, the analyst tells investors in a research note. Clear adds that Beam owns 17% of private company Orbital Therapeutics, which amounts to $255M in its recently announced takeout.
Wedbush
David Nierengarten
Neutral
downgrade
$14 -> $9
2025-10-30
Reason
Wedbush
David Nierengarten
Price Target
$14 -> $9
2025-10-30
downgrade
Neutral
Reason
Wedbush analyst David Nierengarten lowered the firm's price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Neutral rating on the shares. The firm notes FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z following a voluntary pause due to new safety signals of symptomatic transaminase elevation and bilirubin increase. A formal Clinical Hold Letter will be provided within 30 days. Wedbush reiterates its position that these safety signals appear target-specific rather than a class effect of LNP delivery, and views recent price action for Beam Therapeutics (BEAM) and Prime Medicine (PRME) as a buying opportunity. For Intellia's nex-z, even after the clinical hold is resolved, the firm expects reduced market uptake against competing siRNA therapies, which do not have substantial reports of hepatic toxicity and can be discontinued in the case of adverse events.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-04-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-04-07
Reiterates
Strong Buy
Reason
B of A Securities
Alec Stranahan
Hold
to
Strong Buy
Upgrades
$42
2025-03-28
Reason
B of A Securities
Alec Stranahan
Price Target
$42
2025-03-28
Upgrades
Hold
to
Strong Buy
Reason
Cantor Fitzgerald
Rick Bienkowski
Buy
Reiterates
n/a
2025-03-12
Reason
Cantor Fitzgerald
Rick Bienkowski
Price Target
n/a
2025-03-12
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Beam Therapeutics Inc (BEAM.O) is -6.20, compared to its 5-year average forward P/E of -10.83. For a more detailed relative valuation and DCF analysis to assess Beam Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.83
Current PE
-6.20
Overvalued PE
-2.83
Undervalued PE
-18.82

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.90
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.52
Undervalued EV/EBITDA
-18.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
147.91
Current PS
0.00
Overvalued PS
450.51
Undervalued PS
-154.70
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 161.22% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

BEAM News & Events

Events Timeline

(ET)
2025-12-03
12:10:00
Beam Therapeutics Stock Rises 11.3% to $26.00
select
2025-11-11 (ET)
2025-11-11
16:27:07
Richard Pazdur Named Director of CDER by FDA
select
link
2025-11-04 (ET)
2025-11-04
07:04:11
Beam Therapeutics Announces Q3 Earnings Per Share of $1.10, Exceeding Consensus Estimate of $1.03
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
12-03NASDAQ.COM
Wednesday's Top Performers: Biotechnology and Trucking Stocks

  • Trucking Sector Performance: Trucking shares have shown relative strength, increasing by approximately 3.8% overall, with Universal Logistics Holdings and Werner Enterprises leading the gains at 6.5% and 6.4%, respectively.

  • Market Highlights: The performance of trucking stocks was highlighted in a video segment focusing on sector leaders, alongside biotechnology stocks.

  • Author's Perspective: The views expressed in the article are those of the author and do not necessarily represent the opinions of Nasdaq, Inc.

  • Date of Report: The information was reported on Wednesday, indicating a specific timeframe for the stock performance mentioned.

[object Object]
Preview
3.0
11-27NASDAQ.COM
BEAM vs. NTLA: Which Gene Editing Company Offers Greater Investment Potential?

  • Beam Therapeutics Overview: Beam Therapeutics is developing innovative gene therapies using its proprietary base-editing technology, with candidates like BEAM-101 for sickle cell disease showing promising early results. However, the company faces challenges due to its lack of approved products and reliance on partnerships for growth.

  • Intellia Therapeutics Overview: Intellia Therapeutics focuses on in vivo gene therapies and is advancing late-stage candidates like lonvo-z for hereditary angioedema. The company recently faced setbacks with its nex-z candidate due to a clinical hold from the FDA, raising safety concerns.

  • Investment Comparison: While both companies are in the gene editing space, Beam Therapeutics is considered a safer investment despite its higher valuation, as it has a broader pipeline and less immediate risk compared to Intellia, which is dealing with regulatory issues.

  • Market Performance: Year-to-date, Beam's stock has gained 1%, while Intellia's has dropped 27%. Both companies hold a Zacks Rank of #3 (Hold), indicating uncertainty in choosing between them, but Beam's fundamentals and recent stock performance suggest potential for growth.

[object Object]
Preview
6.0
11-24Benzinga
Evercore ISI Group Begins Coverage of Beam Therapeutics with Outperform Rating and Sets Price Target at $35

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

  • Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters, enhancing their trading strategies.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and experiences.

  • Market Winning Tools: The platform is designed to provide traders with the tools and information necessary to succeed in their trading endeavors.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Beam Therapeutics Inc (BEAM) stock price today?

The current price of BEAM is 28.91 USD — it has increased 8.12 % in the last trading day.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s business?

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

arrow icon

What is the price predicton of BEAM Stock?

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 41.90 USD with a low forecast of 21.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s revenue for the last quarter?

Beam Therapeutics Inc revenue for the last quarter amounts to 9.70M USD, decreased -32.03 % YoY.

arrow icon

What is Beam Therapeutics Inc (BEAM)'s earnings per share (EPS) for the last quarter?

Beam Therapeutics Inc. EPS for the last quarter amounts to -1.10 USD, decreased -5.98 % YoY.

arrow icon

What changes have occurred in the market's expectations for Beam Therapeutics Inc (BEAM)'s fundamentals?

The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -15.4% over the past three months. During the same period, the stock price has changed by 38.46%.
arrow icon

How many employees does Beam Therapeutics Inc (BEAM). have?

Beam Therapeutics Inc (BEAM) has 483 emplpoyees as of December 05 2025.

arrow icon

What is Beam Therapeutics Inc (BEAM) market cap?

Today BEAM has the market capitalization of 2.93B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free